Modeling Pegylated Liposomal Doxorubicin-Induced Hand-Foot Syndrome and Intestinal Mucositis in Zebrafish

OncoTargets and Therapy - New Zealand
doi 10.2147/ott.s63785
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Emerging Pharmacotherapies in Ovarian Cancer: Focus on Pegylated Liposomal Doxorubicin

Clinical Medicine Reviews in Women's Health
2010English

Efficacy and Safety of Non-Pegylated Liposomal Doxorubicin in Metastatic Breast Cancer Therapy

OnCOReview
Oncology
2017English

Pegylated Liposomal Doxorubicin in the Treatment of Primary Cutaneous T-Cell Lymphomas

Haematologica
Hematology
2007English

Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast Cancer

PLoS ONE
Multidisciplinary
2013English

Safety and Efficacy of Pegylated Liposomal Doxorubicin in HIV-associated Kaposi’s Sarcoma

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2009English

Case Series of Docetaxel-Induced Dorsal Hand–foot Syndrome

Therapeutic Advances in Drug Safety
Pharmacology
2018English

Prospective Multicenter Study of Pegylated Liposomal Doxorubicin Treatment in Patients With Advanced or Refractory Mycosis Fungoides or Sézary Syndrome

Archives of Dermatology
2008English

A Systematic Review and Economic Evaluation of Pegylated Liposomal Doxorubicin Hydrochloride for Ovarian Cancer

Health Technology Assessment
MedicineHealth Policy
2002English

A Retrospective Analysis of Pegylated Liposomal Doxorubicin in Ovarian Cancer: Do We Still Need It?

Journal of Ovarian Research
GynecologyOncologyObstetrics
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy